Subsequent event risk in individuals with established coronary heart disease : design and rationale of the GENIUS-CHD Consortium by Patel, R et al.
Circ Genom Precis Med. 2019;12:e002470. DOI: 10.1161/CIRCGEN.119.002470 April 2019 145
BACKGROUND: The Genetics of Subsequent Coronary Heart Disease 
(GENIUS-CHD) consortium was established to facilitate discovery and 
validation of genetic variants and biomarkers for risk of subsequent CHD 
events, in individuals with established CHD.
METHODS: The consortium currently includes 57 studies from 18 
countries, recruiting 185 614 participants with either acute coronary 
syndrome, stable CHD, or a mixture of both at baseline. All studies 
collected biological samples and followed-up study participants 
prospectively for subsequent events.
RESULTS: Enrollment into the individual studies took place between 1985 
to present day with a duration of follow-up ranging from 9 months to 
15 years. Within each study, participants with CHD are predominantly of 
self-reported European descent (38%–100%), mostly male (44%–91%) 
with mean ages at recruitment ranging from 40 to 75 years. Initial 
feasibility analyses, using a federated analysis approach, yielded expected 
associations between age (hazard ratio, 1.15; 95% CI, 1.14–1.16) per 
5-year increase, male sex (hazard ratio, 1.17; 95% CI, 1.13–1.21) and 
smoking (hazard ratio, 1.43; 95% CI, 1.35–1.51) with risk of subsequent 
CHD death or myocardial infarction and differing associations with other 
individual and composite cardiovascular endpoints.
CONCLUSIONS: GENIUS-CHD is a global collaboration seeking to 
elucidate genetic and nongenetic determinants of subsequent event risk 
in individuals with established CHD, to improve residual risk prediction 
and identify novel drug targets for secondary prevention. Initial analyses 
demonstrate the feasibility and reliability of a federated analysis approach. 
The consortium now plans to initiate and test novel hypotheses as well as 
supporting replication and validation analyses for other investigators.
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Major public health initiatives and policy chang-es, along with advances in drug and inter-ventional therapies have significantly reduced 
cardiovascular morbidity and mortality in most high-in-
come countries.1–3 However, the improved survival rates 
following an initial presentation with coronary heart 
disease (CHD) has, paradoxically, led to a growing num-
ber of patients living with established CHD (eg, 16M 
in the United States and 3M in the United Kingdom)4,5 
who remain at substantially high risk of subsequent car-
diovascular events. These include myocardial infarction 
(MI), repeated revascularizations but also heart failure, 
stroke, and sudden death.4
Despite a large body of knowledge on the patho-
physiology of first CHD events in general populations,6,7 
little is known about factors that influence disease pro-
gression or subsequent events in patients with estab-
lished CHD, beyond those consequent to the acute 
index event in the short-term (such as biomarkers of 
myocardial dysfunction or necrosis, left ventricular func-
tion, or arrhythmia).8 As a result, although guidelines 
and treatment thresholds have progressively evolved 
over the past 2 decades, the targeted risk factors per 
se have remained largely unaltered.9 Novel therapies 
beyond lipid lowering, antiplatelet agents, and drugs 
recommended for high blood pressure and heart fail-
ure have been slow to emerge. Importantly, multiple 
novel and existing agents (eg, darapladib, varespladib, 
and folic acid) have failed in very late stage clinical 
development despite promising observational data.10–13 
In contrast, some traditional risk factors, such as obe-
sity, which show robust associations with initial CHD 
onset,14 continue to show inverse or null associations 
with subsequent events once CHD has developed.15
Ultimately, the high (residual) risk in individuals with 
existing CHD despite optimal contemporary therapy 
emphasizes the need for studying risk of subsequent 
events and their related causal pathways. For exam-
ple, in the intervention arm of the IMPROVE-IT study 
(Vytorin Efficacy International Trial), despite simvastatin 
and ezetimibe treatment following an acute coronary 
syndrome, at 7 years, almost a third of participants 
experienced the primary end point (a composite of 
cardiovascular death, major coronary event, coronary 
revascularization, or nonfatal stroke).16 Similarly, in 
the FOURIER trial (Further Cardiovascular Outcomes 
Research with PCSK9 [proprotein convertase subtilisin-
kexin type 9] Inhibition in Subjects with Elevated Risk), 
almost 10% of patients with established but stable 
CVD, experienced an event at 2.2 years despite high-
intensity statin and PCSK9 inhibition, with achieved 
median LDL-C (low-density lipoprotein cholesterol) lev-
els of 30 mg/dL.17 These data point to the existence of 
risk factors beyond traditional ones such as LDL-C, and 
the need to elucidate their related causal pathways.18 
By studying those with established CHD at high risk of 
subsequent events, we plan to gain novel insights into 
other drivers of atherosclerosis or features that identify 
patients who may benefit most from novel therapies.9 
Genetic and biomarker studies in these individuals may 
help identify novel molecular pathways and future drug 
targets with the goal of advancing precision medicine.
In the absence of a single-large resource to study 
the determinants of coronary heart disease prognosis, 
we have established the Genetics of Subsequent CHD 
(GENIUS-CHD) consortium.19 Assembling studies from 
across the globe that have recruited patients with dif-
ferent types of CHD at baseline, have acquired prospec-
tive follow-up, and have stored biological specimens, 
or genetic data, the consortium aims to: (1) investigate 
genetic and nongenetic determinants of risk for subse-
quent CHD, systematically and at scale and (2) facilitate 
access to data and expertise, as a platform to foster 
collaboration among investigators working in the field.
Here, we describe the design of the consortium, 
including details of participating studies, available data, 
and samples, as well as the governance procedures and 
the consortium’s approach to data sharing and collabo-
ration to further advance the stated scientific aims. In 
addition, we present some early findings from an inves-
tigation of the association of patient characteristics and 
certain routinely recorded measures on the risk of sub-
sequent events among patients with different types of 
CHD at baseline.
METHODS
In accordance with Transparency and Openness Promotion 
Guidelines, the data, analytic methods, and study materi-
als will be made available to other researchers for purposes 
of reproducing the results or replicating the procedures. 
Participating studies received local institutional review board 
approval and included patients who had provided informed 
consent at the time of enrollment. The central analysis sites 
also received waivers from their local institutional review 
board for collating and analyzing summary-level data from 
these individual studies. Full details on the eligibility criteria, 
definitions of terminology, management of the consortium, 
and planned projects are provided in Materials in the Data 
Supplement.
RESULTS
The design and structure of the GENIUS-CHD consor-
tium are presented in Figure  1. Studies meeting the 
main eligibility criteria were identified and invited to 
participate (Methods in the Data Supplement). In brief, 
studies are eligible to join the GENIUS-CHD consortium 
if they meet 3 inclusion criteria: (1) included individuals 
with established CHD (defined as the presence of or 
confirmed history of acute coronary syndrome at base-
line, or of coronary artery disease as evidenced by any 
revascularization procedure (percutaneous coronary 
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intervention or bypass surgery) or demonstrable plaque 
in any epicardial vessel on direct coronary imaging); 
(2) acquired prospective follow-up of participants with 
ascertainment of one or more subsequent cardiovascu-
lar disease events as well as all-cause mortality; and (3) 
had stored blood samples, which are viable and suitable 
for DNA and biomarker analysis or previously collected 
such data before sample depletion.
At the time of writing, 57 studies from 18 coun-
tries are participating in the consortium and are listed 
in Table 1. Please refer to www.genius-chd.org for an 
updated list. Brief narrative descriptions of each study 
are provided in Methods in the Data Supplement.
The majority of studies are either investigator-led 
clinical cohorts (n=42), but clinical trials (n=10) and 
nested case-cohort (inception-study design) studies 
(n=5) are also included. Of the total, 23 studies have 
included participants at the time of an acute coronary 
syndrome, while the remainder recruited those with 
stable CHD or a mixture of the 2 (eg, from cardiac cath-
eterization labs). Collectively, 185 614 participants have 
been enrolled with CHD at baseline (including 812 803 
person-years of follow-up); of which 170 343 are of self-
reported European descent. Recruitment times varied 
between studies, ranging from the earliest recruitment 
in 1985 to studies that remain actively recruiting to the 
present day. All studies enrolled patients >18 years of 
age, although one study exclusively recruited only those 
with premature CHD (MI <45 years), while another 
recruited only older subjects (>70 years). The overall 
mean age within each study reflects this heterogeneity, 
ranging from 40 to 75 years of age, and proportion of 
male sex ranging from 44% to 91% (Table 1).
Available Data
Core Phenotypes
All studies collected data on age, sex, and ethnicity. Risk 
factor data are available for diabetes mellitus, obesity, 
and smoking status in almost all participating studies 
(96%), while data on concentrations of routine blood 
lipids (total cholesterol, LDL-C, HDL-C [high-density 
lipoprotein cholesterol], and triglycerides; 84%), and 
blood pressure values at enrollment (82%) were col-
lected by the majority of studies. Data on statin use at 
baseline are available in 90% of all participating studies 
(Table 2).
Figure 1. Overview of the Genetics of Subsequent Coronary Heart Disease (GENIUS-CHD) consortium, illustrating inclusion criteria and governance 
structure.  
Following project approval by the steering committee, analyses scripts are prepared and distributed to all members, with sharing of summary-level outputs before 
meta-analysis at the coordinating centers. Further details can be found at www.genius-chd.org. QC indicates quality control.
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Additional Phenotypes
A list of selected additional phenotypes available by 
study is presented in Table I in the Data Supplement. Of 
note, 79% have available data on plasma CRP (C-reac-
tive protein), while coronary disease burden informa-
tion, from invasive angiography is available in 52% of 
studies. Finally, over a third of studies have also collect-
ed data on physical activity (38%) and socioeconomic 
status (37%).
Samples
Stored samples are available in most studies for future 
assay testing and stored frozen. The majority have stored 
plasma (75%), while others also have serum, blood 
EDTA, RNA, and urine (Table II in the Data Supplement).
DNA and Genotyping
More than two-thirds of the studies have DNA still avail-
able, either preextracted or as whole blood collected 
in EDTA and stored for future genotyping. All studies 
within the consortium have performed genotyping in 
some capacity, with genome-wide data available in a 
subset of studies (Table III in the Data Supplement).
Subsequent Events and Follow-Up
The most commonly collected end point was all-cause 
death, collected by all but 2 studies. CHD death during 
follow-up was collected in 70% of studies, while inci-
dent MI was reported by 82% of studies. Studies ascer-
tained end points through different means, including 
telephone contact, in-person patient interviews, clinical 
chart reviews, and linkage to national mortality registers 
and hospital records (Table IV in the Data Supplement).
Power Calculations
Empirical power was estimated based on a conservative 
sample size of 150 000 subjects with an event rate of 
10% (across the entire follow-up period with a mean 
of about 5 years); Figure 2. Given that the GENIUS-CHD 
consortium is designed to answer multiple questions, 
power was estimated for a range of genetic single 
nucleotide polymorphisms (SNPs) and nongenetic (bio-
markers and clinical risk factors) effects.
Minor allele frequencies of 0.01, 0.05, 0.10, and 
0.25 were examined, representing rare to common 
SNPs. For each minor allele frequency, power was calcu-
lated for a range of plausible SNP effects on biomarkers 
(mean difference [μ] 0.01, 0.03, and 0.05) and clinical 
end points (odds ratios of 1.02, 1.05, and 1.10). For 
the association of SNPs with biomarkers, power was 
80% (α=0.05) or more unless the SNP was rare (minor 
allele frequency of 0.01) or the effect size was small 
(eg, 0.01 per allele). For the association of SNPs with 
clinical end points, power was close to 80% when the 
effect size was large (odds ratio ≥1.10) or the minor 
allele frequency was ≥0.10.
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Power of observational (ie, nongenetic) analysis was 
>99% for both continuous and binary exposures unless 
the odds ratio was close to 1. In addition to continu-
ous and binary outcome data, GENIUS-CHD also collects 
time-to-event data. Given the similarity (in most empiri-
cal settings) between odds ratio and hazard ratios,20 sim-
ilar power is to be expected for time-to-event analysis.
Initial Analysis
To examine the feasibility of the federated analysis 
approach, we sought to collect data on participant char-
acteristics, cardiovascular and mortality outcomes and 
association analyses with common clinical exposures. A 
standardized dataset was developed, with a federated 
analysis conducted using standardized statistical scripts. 
The summary-level outputs generated were then shared 
with the coordinating centers for aggregating and meta-
analysis (Methods in the Data Supplement).
Participant Characteristics
Detailed characteristics of participants by study are pre-
sented in Table 2. Prevalence of risk factors varied by 
study, with diabetes mellitus ranging from 4% to 76%; 
smoking from 8% to 79%. Mean total cholesterol by 
study ranged from 166.3 to 239.8 mg/dL, mean body 
mass index ranged from 24.8 to 30.2 kg/m2 and mean 
systolic blood pressure from 117 to 153 mm Hg. The 
proportion of participants with prior revascularization 
or MI was high in most studies reflecting the inclusion 
criteria for the consortium (Table 2).
Review of returned outputs from the federated anal-
ysis revealed good quality data with estimates falling 
within expected ranges for age, sex, and other vari-
ables, such as body mass index (Figure I in the Data 
Supplement).
Figure 2. Figure illustrating empirical power for detecting different effect sizes for biomarker variance and clinical events for both α 0.05 and 
0.0001, by varying minor allele frequencies, for a conservative total number of 150 000 with an event rate of 10%.  
MAF indicates minor allele frequency; and OR, odds ratio.
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End Points
The primary end point preselected for the study was 
a composite of coronary death or MI (CHD death/
MI). Mean follow-up was estimated in each study and 
ranged between 9 months and 15 years. In total, we 
estimated over 748 000 person-years of follow-up were 
available for the primary end point analysis.
Information was collected on 10 subsequent event 
end points in the initial feasibility analysis. Across all 
studies, the most frequently occurring event during 
prospective follow-up was the composite of all cardio-
vascular events (27%); followed by revascularization 
(21.8%); all-cause mortality (15%); coronary death or 
MI (14.2%); MI (10.7%); cardiovascular death (8.3%); 
coronary death (8%); heart failure (6.3%); all stroke 
(3.6%); and ischemic stroke (3.4%).
Association Analyses
As a feasibility analysis, we examined associations 
between age, male sex, and smoking with the primary 
end point CHD death/MI as well as with the 9 other 
secondary end points, to investigate any differential 
associations across discrete subsequent events.
In analyses unrestricted by race or type of CHD at 
baseline, but adjusted for sex, there was a strong asso-
ciation between each 5-year increment in age with sub-
sequent risk of the primary end point of CHD death/
MI (hazard ratio [HR] 1.15; 95% CI, 1.14–1.16). The 
largest observed HRs were for all-cause mortality (HR, 
1.36; 95% CI, 1.35–1.37), cardiovascular death (HR, 
1.36; 95% CI, 1.35–1.38), and heart failure (HR, 1.25; 
95% CI, 1.24–1.27), while a smaller risk increase was 
observed for MI (HR, 1.06; 95% CI, 1.05–1.07). The risk 
of future revascularization, however, showed a modest 
inverse association with increasing age (HR, 0.98; 95% 
CI, 0.98–0.99; Figure 3).
Male sex was a risk factor for CHD death/MI (HR, 
1.17; 95% CI, 1.13–1.21) and other coronary and mor-
tality end points (Figure 4) after adjustment for age. In 
particular, the largest observed HR was for risk of revas-
cularization, which was considerably higher in males 
(HR, 1.24; 95% CI, 1.20–1.27). In contrast, there was 
no strong evidence for an association between male sex 
and risk of stroke (ischemic or any stroke; Figure 4).
Finally, in analyses adjusted for age and sex, cur-
rent smoking (compared to prior or never smoking) at 
the time of enrollment showed a strong association 
with risk of future CHD death/MI (HR, 1.43; 95% CI, 
1.35–1.51). Similarly, smoking was associated with an 
increased risk of all-cause mortality (HR, 1.53; 95% CI, 
1.47–1.58) and an increased risk of all other end points, 
although there was no strong evidence for an associa-
tion with incident revascularization (HR, 1.02; 95% CI, 
0.99–1.05; Figure 5).
When stratified by type of CHD at enrollment, that 
is, among those presenting with an acute event, those 
with stable CAD without ever having had an MI and 
those with stable CAD and a prior MI, the findings 
were similar and directionally concordant to nonstrati-
fied analyses described above, for all end points (data 
not shown).
Figure 3. Meta-analyses of the associations 
between age (per 5-year intervals) and 
different end points, adjusted for sex. Esti-
mates are presented as hazard ratios (HRs) with 
95% CI. CHD indicates coronary heart disease; 
CVD, cardiovascular disease; and MI myocardial 
infarction.
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DISCUSSION
The GENIUS-CHD Consortium is a global collaborative 
effort engaging 57 studies, including almost 185 000 
patients with established CHD, for whom genetic 
and prospective follow-up data are available. It brings 
together over 170 domain experts, including clinicians, 
data scientists, geneticists, and epidemiologists, all 
engaged in improving our understanding of the deter-
minants of subsequent event risk in these patients. 
With an agreed governance structure and a proven 
federated analysis approach, we anticipate that this 
consortium will be a valuable long-term resource for 
genetic and nongenetic research in this field.
Genetic association studies for CHD disease progres-
sion, recurrence, and adverse events after a CHD event 
may have particular utility for identifying novel causal 
pathways and therapeutic targets that may be different 
than those for first events, a concept recently supported 
by research in other disease areas.21 However, informa-
Figure 4. Meta-analyses of the associations 
between male sex and different end points, 
adjusted for age.  
Estimates are presented as hazard ratios (HRs) 
with 95% CI. CHD indicates coronary heart 
disease; CVD, cardiovascular disease; and MI, 
myocardial infarction.
Figure 5. Meta-analyses for the associa-
tions between smoking at coronary heart 
disease (CHD) indexing event compared to 
not smoking and for different end points, 
adjusted for age and sex.  
Estimates are presented as hazard ratios (HRs) 
with 95% CI. CVD indicates cardiovascular 
disease; and MI, myocardial infarction.
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tion on the determinants of subsequent CHD event risk 
is scarce, in contrast to the extensive knowledge about 
risk factors for a first CHD event. This disparity is due, 
in part, to the relatively small sample sizes of individual 
studies in the secondary prevention setting. While larg-
er registry and electronic health care records efforts will 
result in higher numbers, they typically suffer from the 
lack of necessary depth of phenotyping, accuracy, and 
availability of biospecimens to infer further biological 
insights.22,23 In contrast, large population studies with 
detailed phenotyping have relatively small numbers of 
mostly stable CHD patients, who have survived many 
years after their index event.24,25 By bringing together 
multiple investigator-led studies, the GENIUS-CHD con-
sortium aims to address and overcome this major limi-
tation to subsequent CHD risk research.
Importantly, the scale and depth of the GENIUS-CHD 
consortium offer greater scope to tackle key challenges 
within subsequent CHD risk-related research. First, CHD 
is a heterogeneous phenotype, consisting of stable, 
unstable, and pathologically distinct subtypes, which 
have often been combined for individual studies to 
satisfy the need for statistical power. With the sample 
size available in GENIUS-CHD, we anticipate being able 
to disaggregate CHD into more precise subphenotypes 
such as acute versus stable CHD at baseline, or those 
with versus without prior MI, which may help uncover 
relevant biological differences.26 Additional stratifica-
tion on variables such as sex, time period of recruitment, 
duration of follow-up, country of study, LV function and 
treatment (such as statin, blood pressure lowering, and 
antiplatelet agent use) will also be possible, providing 
greater insights into the modifying influences of these 
variables on outcome.
A major strength of the consortium is the use of a 
federated analysis approach that permits individual lev-
el analysis without the need for sharing either samples 
or the individual datasets themselves, thereby overcom-
ing major privacy and governance hurdles. The effort 
has been successful because (1) participation is entirely 
voluntary, with studies only participating in those analy-
ses they feel are of value, or to which they have the 
capacity to contribute; (2) ownership of all data and 
samples remain with the principal investigator and are 
not shared nor stored centrally; and (3) there are open 
and transparent governance procedures. Our feasibility 
analysis has demonstrated that this federated approach 
works well and yields results that are consistent and 
suitable for high-quality meta-analysis.
Indeed, supported by this initial feasibility analysis, 
our findings demonstrate the validity of the data col-
lected by confirming the anticipated associations of 
increasing age, male sex, and current smoking with 
higher risks of subsequent CHD death/MI during follow-
up. Furthermore, by exploring multiple individual and 
composite end points, we can begin to unravel associa-
tions not discoverable in smaller studies. For example, 
we find that the risk of incident revascularization is low-
er with advancing age but higher for male sex and neu-
tral for smoking. Plausible explanations may exist for 
each of these findings (eg, an association induced by 
clinical practice, with fewer older people being offered 
invasive treatments), but importantly they highlight the 
value of exploring multiple end points at an appropriate 
scale. This is especially relevant when exploring novel 
biomarkers or drug targets as these may, in turn, be 
used to inform clinical testing strategies and choice of 
end points to study in trials.
By virtue of the expertise it has assembled, the 
consortium is also well placed to address important 
methodological issues surrounding prognosis research 
in general. For example, selection bias is a key con-
cern, whereby it is conceivable that those at highest 
risk may die early and not enter any of the member 
studies for evaluation (survival bias), or selection on an 
indexing event itself may distort patient characteristics 
and impact association findings (index event bias).27 
In addition, treatment effects may alter the trajectory 
of disease by stabilizing or regressing plaque burden 
or altering baseline risk, such as with high-dose statin 
or PCSK9 inhibitor use.17,28 To address these and other 
issues, the consortium has established working groups 
of relevant national and international experts to explore 
the extent and impact of such biases/effects and if 
needed, to develop approaches to address these.29
There are inherent challenges to overcome when 
working with diverse multiple studies, including varia-
tions in definitions and processes for data collection 
and curation across different studies in different centers 
and different countries. The consortium members have 
attempted to standardize common data elements, for 
example, the measurement units for quantitative traits. 
Variability between studies will persist, but we antici-
pate that the overall size of the effort will help reduce 
the impact of such study level heterogeneity on any 
findings, which will also be explored through subgroup 
analyses where possible (eg, country, study size, and year 
of first recruitment). Analytical challenges will addition-
ally include dealing with variability in length of follow-
up across studies, handling multiple subsequent events 
along with competing risks, as well as confounding by 
treatment and selection biases as described above. The 
collective experience of the consortium members will 
be leveraged to address these as carefully as possible 
within each future analysis. Finally, factors influencing 
enrollment into genetic studies of CHD may limit the 
generalizability of findings. Men are over represented in 
participating CHD studies, partly reflecting sex-differen-
tial prevalence of disease but also underpinning a wider 
concern about underinvestigation of women, who may 
be inadvertently excluded given that entry criteria for 
most studies relies on documented presence of CHD. 
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Similarly, many studies in the consortium have recruited 
mostly Europeans, limiting the opportunity to explore 
hypotheses in other ethnic groups. The steering com-
mittee is conscious of these imbalances and is actively 
seeking studies enriched for women and non-Europe-
an participants to join the collaboration. In summary, 
the GENIUS-CHD consortium is a global collaboration 
among investigators who have recruited patients with 
CHD into multiple individual studies, seeking to gain 
a better understanding of subsequent CHD event risk 
and enhance secondary prevention. It seeks to be an 
open, collegiate, and transparent effort and we invite 
investigators with suitable studies to join and collective-
ly enhance research efforts in this domain.
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